On Tuesday, Inovio Pharmaceuticals Inc (NASDAQ: INO) was -3.45% drop from the session before settling in for the closing price of $4.35. A 52-week range for INO has been $3.85 – $14.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 60.80%. When this article was written, the company’s average yearly earnings per share was at 28.41%. With a float of $25.80 million, this company’s outstanding shares have now reached $26.05 million.
Let’s determine the extent of company efficiency that accounts for 122 employees. In terms of profitability, gross margin is -767.0%, operating margin of -58709.67%, and the pretax margin is -12414736.82%.
Inovio Pharmaceuticals Inc (INO) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Inovio Pharmaceuticals Inc stocks. The insider ownership of Inovio Pharmaceuticals Inc is 1.14%, while institutional ownership is 33.08%.
Inovio Pharmaceuticals Inc (INO) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 28.41% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 41.50% during the next five years compared to 13.49% growth over the previous five years of trading.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Trading Performance Indicators
You can see what Inovio Pharmaceuticals Inc (INO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.88. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 548.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.48, a number that is poised to hit -0.92 in the next quarter and is forecasted to reach -3.46 in one year’s time.
Technical Analysis of Inovio Pharmaceuticals Inc (INO)
Looking closely at Inovio Pharmaceuticals Inc (NASDAQ: INO), its last 5-days average volume was 0.34 million, which is a drop from its year-to-date volume of 0.4 million. As of the previous 9 days, the stock’s Stochastic %D was 69.72%. Additionally, its Average True Range was 0.28.
During the past 100 days, Inovio Pharmaceuticals Inc’s (INO) raw stochastic average was set at 4.13%, which indicates a significant decrease from 24.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.27% in the past 14 days, which was higher than the 53.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.21, while its 200-day Moving Average is $8.55. However, in the short run, Inovio Pharmaceuticals Inc’s stock first resistance to watch stands at $4.49. Second resistance stands at $4.78. The third major resistance level sits at $4.95. If the price goes on to break the first support level at $4.03, it is likely to go to the next support level at $3.86. Should the price break the second support level, the third support level stands at $3.57.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Key Stats
There are 26,100K outstanding shares of the company, which has a market capitalization of 109.62 million. As of now, sales total 830 K while income totals -135,120 K. Its latest quarter income was 100 K while its last quarter net income were -32,240 K.
